Compare Aurora Cannabis Inc (ACB) vs Brunswick Corporation (BC) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

BC trades at $77.33, down 2.23% today, with a bearish technical signal and mixed earnings history. Revenue declined to $5.36B in 2025 with a net loss of $137.30M, though recent quarters beat expectations. The company maintains strong analyst support with a $86.40 consensus target and announced a $0.44 dividend for H1-26. Cash flow improved to a near-neutral -$11M in 2025 from deeper losses in prior years.

Outlook is cautious due to profitability challenges and high P/E of 73.92, but expansion news like Freedom Boat Club's 450th location offers growth potential. Risks include sustained negative margins and debt levels, while institutional buy ratings suggest confidence in a turnaround if execution improves.